We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
126
DELISTED
Blueprint Medicines
BPMC
| $27.5M | 0.19% |
312,950
-38,931
| -11% | -$3.57M |
|
127
VF Corp
VFC
$6.68B
| $27.5M | 0.19% |
334,771
+137,685
| +70% | +$11.5M |
|
128
Best Buy
BBY
$18B
| $27.4M | 0.19% |
228,955
+61
| +0% | +$7.12K |
|
129
CBRE Group
CBRE
$40.8B
| $27.4M | 0.19% |
319,364
-85,855
| -21% | -$7.33M |
|
130
PepsiCo
PEP
$186B
| $26.9M | 0.18% |
181,533
-269,649
| -60% | -$39.3M |
|
|
MRSN
131
DELISTED
Mersana Therapeutics
MRSN
| $26.8M | 0.18% |
78,916
+34,029
| +76% | +$12.9M |
|
|
132
Bristol-Myers Squibb
BMY
$127B
| $26.7M | 0.18% |
399,383
-1,385,399
| -78% | -$90.3M |
|
133
Zimmer Biomet
ZBH
$17.7B
| $26.6M | 0.18% |
165,182
+152,985
| +1,254% | +$24.8M |
|
134
Iovance Biotherapeutics
IOVA
$2.23B
| $26.6M | 0.18% |
1,020,426
+428,376
| +72% | +$11.1M |
|
135
Synchrony
SYF
$23.7B
| $26.5M | 0.18% |
546,442
+433,204
| +383% | +$19.7M |
|
|
HOLX
136
DELISTED
Hologic
HOLX
| $26.4M | 0.18% |
396,183
-559,548
| -59% | -$37.4M |
|
|
WORK
137
DELISTED
Slack Technologies, Inc.
WORK
| $26.2M | 0.18% |
591,282
+54,819
| +10% | +$2.35M |
|
138
Novavax
NVAX
$1.23B
| $26.2M | 0.18% |
123,323
+50,774
| +70% | +$9.3M |
|
|
DCPH
139
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $25.9M | 0.18% |
708,117
+531,462
| +301% | +$20.6M |
|
140
Regions Financial
RF
$26.3B
| $25.9M | 0.18% |
1,284,435
+551,078
| +75% | +$11.9M |
|
141
Illinois Tool Works
ITW
$81.4B
| $25.8M | 0.18% |
115,227
+87,442
| +315% | +$20M |
|
142
Tetra Tech
TTEK
$8.23B
| $25.7M | 0.18% |
1,053,440
+366,640
| +53% | +$9.22M |
|
143
Mettler-Toledo International
MTD
$26.8B
| $25.5M | 0.17% |
18,406
+16,283
| +767% | +$21M |
|
144
TJX Companies
TJX
$170B
| $25M | 0.17% |
371,074
+158,702
| +75% | +$10.8M |
|
145
Qorvo
QRVO
$7.63B
| $25M | 0.17% |
127,763
-35,336
| -22% | -$6.52M |
|
146
Automatic Data Processing
ADP
$100B
| $25M | 0.17% |
125,778
+44,102
| +54% | +$8.57M |
|
147
Halozyme
HALO
$9.72B
| $24.9M | 0.17% |
548,930
-184,812
| -25% | -$8.18M |
|
148
West Pharmaceutical
WST
$23.1B
| $24.7M | 0.17% |
68,759
+44,139
| +179% | +$14.6M |
|
149
Cadence Design Systems
CDNS
$90B
| $24.4M | 0.17% |
178,252
-12,203
| -6% | -$1.62M |
|
|
VMW
150
DELISTED
VMware, Inc
VMW
| $24.4M | 0.17% |
152,357
-63,103
| -29% | -$10.1M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.